CellTypeYC W26 landing page report.
← Back to YC W26

Your landing page’s weakest score is Trust.

Fix Trust

Score over time

706560555045Recursion 63 on Jun 26 (Wayback)Recursion 62 on Jul 7 (Wayback)Recursion 64 on Jul 22 (Wayback)Recursion 50 on Aug 10 (Wayback)Recursion 50 on Aug 27 (Wayback)Recursion 53 on Sep 11 (Wayback)Recursion 66 on Sep 20 (Live)Insilico Medicine 54 on Jun 16 (Wayback)Insilico Medicine 55 on Jun 27 (Wayback)Insilico Medicine 56 on Jul 15 (Wayback)Insilico Medicine 56 on Jul 26 (Wayback)Insilico Medicine 56 on Aug 10 (Wayback)Insilico Medicine 57 on Sep 9 (Wayback)Insilico Medicine 54 on Sep 22 (Live)Cellarity 51 on Sep 22 (Live)Deep Genomics 53 on Apr 13 (Wayback)Deep Genomics 55 on May 20 (Wayback)Deep Genomics 53 on Jul 2 (Wayback)Deep Genomics 51 on Aug 31 (Wayback)Deep Genomics 52 on Sep 15 (Wayback)Deep Genomics 48 on Sep 22 (Live)Noetik 66 on Sep 22 (Live)CellType 63 on Apr 13 (Wayback)CellType 61 on May 19 (Wayback)CellType 62 on Sep 22 (Live)Apr 13May 19Sep 22
Past reportsShow past reportsHide past reports
  1. Sep 22, 202662LiveOverall +1 · Value props −14 · Information hierarchy +10Viewing
  2. May 19, 202661Overall −2 · CTA −10View →
  3. Apr 13, 202663First tracked report — strongest Value props 76, weakest Trust 52View →

Trust

52Fair

Proof that the product is real, competent, and safe to try.

CellType
Insilico Medicine
Recursion
Trust read
CellTypeBanner: "CellType signs major strategic partnership with Senhwa Biosciences"
RecursionUnlocking the First Neuroscience Target for the Recursion and Genentech Collaboration
Insilico MedicinePipeline table rows showing "Out-licensed to Exelixis" and "Out-licensed to Menarini" with Phase I–III progress bars and
CellarityNo visible trust signal identified.
Deep GenomicsNo visible trust signal identified.
NoetikTissue data visualization with labeled gene markers (IFNG, GZMB, PDCD1, IL7R)

CTA

58Fair

Copy, size, verb, cost-feel — does the primary CTA earn the click?

CellType
Recursion
Noetik

Problems

  • 'Request' signals gated, costly click
  • text link, no button footprint
  • visually dwarfed by headline
  • no secondary CTA fallback

Value props

62Fair

Title, subtitle, hero — do they sell the product's true value?

CellType’s headline vagueThe biological world model for drug developmentCellType learns the hidden structure of cellular and molecular state, then turns it into decision systems for drug development.

Working

  • Names the audience: drug development
  • Big category claim signals ambition
  • Partnership banner adds credibility

Could improve

  • No outcome or benefit stated
  • Zero numbers or proof points
  • Hero blob shows nothing about product

Mobile web

62Fair

The phone experience as a first-class citizen.

Mobile web annotations on the mobile capture12
  1. Request Access link — Primary CTA is plain text cropped at the fold edge — not a visible, thumb-sized button.
  2. Hero headline block — Desktop-scale headline wraps into four tall lines, pushing the CTA out of the first viewport.

Information hierarchy

78Fair

Does the design help or inhibit what the page is trying to say?

Information hierarchy annotations on the desktop capture1234
  1. Request Access link — Primary CTA styled as body-weight text link, no button treatment — the quietest element on a page built to drive access requests.
  2. Partnership banner — Full-width black banner with outbound link outranks the CTA in contrast and sits first in the scan path.
  3. Orb overlaps headline — The sphere's edge collides with 'development', muddying the headline's final word instead of framing it.
  4. Low-contrast nav links — Five grey links offer exits, and 'Contact' fades to near-illegible against the background.